nach oben

Erschienen in:

01.11.2010 | Clinical trial

Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons

verfasst von: Umberto Veronesi, Roberto Orecchia, Alberto Luini, Viviana Galimberti, Stefano Zurrida, Mattia Intra, Paolo Veronesi, Paolo Arnone, Maria Cristina Leonardi, Mario Ciocca, Roberta Lazzari, Pietro Caldarella, Nicole Rotmensz, Claudia Sangalli, Daniele Sances, Patrick Maisonneuve

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Intraoperative radiotherapy with electrons (ELIOT) after conservative surgery for breast carcinoma was introduced at the IEO in 1999 as a research programme. The results on 1,822 patients treated from January 2000 to December 2008 are reported. Women with unicentric primary breast carcinoma of less than 2.5 cm in the largest diameter were assessed by imaging. All patients were treated with breast-conserving surgery (quadrantectomy). ELIOT was delivered by two mobile linear accelerators immediately after breast resection with a single dose of 21 Gy. Local side effects of ELIOT were mainly liponecrosis (4.2%) and fibrosis (1.8%). After a mean follow-up of 36.1 months, 42 women (2.3%) developed a local recurrence, 24 (1.3%) a new primary ipsilateral carcinomas and 26 (1.4%) distant metastases as first event. Forty-six women died (2.5%), 28 for breast carcinoma and 18 for other causes. Five- and ten-year survivals were, respectively, 97.4 and 89.7%. ELIOT appears a promising feature in early breast cancer treated with breast conserving surgery, reducing the exposure of normal tissues to radiations and shortening the radiation course from 6 weeks to one single session.

Veronesi U, Saccozzi R, Del Vecchio M et al (1981) Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. New Engl J Med 305:6–11CrossRefPubMed

Veronesi U, Luini A, Del Vecchio M et al (1993) Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Eng J Med 328:1587–1590CrossRef

Veronesi U, Marubini E, Mariani L et al (2001) Radiotherapy after breastconserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 12:997–1003CrossRefPubMed

Whelan TJ, Pignol JP, Levine MN et al (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362(6):513–520CrossRefPubMed

START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EG et al (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9(4):331–341CrossRefPubMed

Kirova YM, Campana F, Savignoni A et al (2009) Institut Curie Breast Cancer Study Group. Breast-conserving treatment in the elderly long-term results of adjuvant hypofractionated and normofractionated radiotherapy. Int J Radiat Oncol Biol Phys 75(1):76–81PubMed

Bernier J, Viale G, Orecchia R et al (2006) Partial irradiation of the breast: old challenges, new solutions. Breast 15:466–475CrossRefPubMed

Orecchia R, Fossati P (2007) Partial breast irradiation: ready for routine? Breast 16(Suppl 2):S89–S297CrossRefPubMed

Vicini FA, Beitsch PD, Quiet CA et al (2005) First analysis of patient demographics, technical reproducibility, cosmesis, and early toxicity: results of the American Society of Breast Surgeons MammoSite breast brachytherapy trial. Cancer 104(6):1138–1148CrossRefPubMed

10.

Orecchia R, Jereczek-Fossa BA, Ciocca M et al (2007) Intraoperative radiotherapy for locally advanced prostate cancer: treatment technique and ultrasound-based analysis of dose distribution. Anticancer Res 27:3471–3476PubMed

11.

Tepper JE, Cohen AM, Wood WC et al (1986) Intraoperative electron beam radiotherapy in the treatment of unresectable rectal cancer. Arch Surg 121:421–423PubMed

12.

Wood WC, Shipley WU, Gunderson LL et al (1982) Intraoperative irradiation for unresectable pancreatic carcinoma. Cancer 49:1272–1275CrossRefPubMed

13.

Veronesi U, Orecchia R, Luini A et al (2001) A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated. Eur J Cancer 37:2178–2183CrossRefPubMed

14.

Veronesi U, Gatti G, Luini A et al (2003) Full-dose intraoperative radiotherapy with electrons during breast conserving surgery. Arch Surg 138:1253–1256CrossRefPubMed

15.

Veronesi U, Orecchia R, Luini A et al (2005) Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery. Experience with 590 cases. Ann Surg 242:101–106CrossRefPubMed

16.

Veronesi U, Gatti G, Luini A et al (2003) Intraoperative radiotherapy for breast cancer: technical notes. Breast J 9:106–112CrossRefPubMed

17.

Ciocca M, Orecchia R, Garibaldi C et al (2003) In vivo dosimetry using radiochromic films during intraoperative electron beam radiation therapy in early-stage breast cancer. Radiother Oncol 69:285–289CrossRefPubMed

18.

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer. Histopathology 19:403–410CrossRefPubMed

19.

Rosen PP, Oberman HA (1993) Tumors of the mammary gland. In: Atlas of tumor pathology, 3rd ser., fasc. 7. Armed Forces Institute of Pathology, Washington, DC, pp 135–156

20.

Viale G, Regan MM, Mastropasqua MG et al (2008) Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100:207–212CrossRefPubMed

21.

Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 16:1227–1232CrossRef

22.

Fisher B, Anderson S, Bryant J et al (2002) Twenty-five-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 8:1233–1241CrossRef

23.

Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378CrossRefPubMed

24.

Kim KJ, Huh SJ, Yang JH et al (2005) Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy. Jpn J Clin Oncol 35:126–133CrossRefPubMed

25.

Veronesi U, Paganelli G, Viale G et al (2006) Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of randomised controlled study. Lancet Oncol 7(12):983–990CrossRefPubMed

26.

Ribeiro GG, Magee B, Swindell R et al (1993) The Christie Hospital breast conservation trial: an update at 8 years from inception. Clin Oncol 5:278–283CrossRef

27.

Reitsamer R, Peintinger F, Kopp M et al (2004) Local recurrence rates in breast cancer patients treated with intraoperative electron-boost radiotherapy versus postoperative external-beam electron-boost irradiation. A sequential intervention study. Strahlenther Onkol 180:38–44CrossRefPubMed

28.

Giraud P, Simon L, Saliou M et al (2005) Respiratory gated radiotherapy: the 4D radiotherapy. Bull Cancer 92:83–89PubMed

29.

Vicini FA, Sharpe M, Kestin L et al (2002) Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 54:1336–1344CrossRefPubMed

30.

Wallner P, Arthur D, Bartelink H et al (2004) Workshop Participants. Commentary. Workshop on Partial Breast Irradiation: State of the art and the science, Bethesda, MD, December 8–10, 2002. J Natl Cancer Inst 96:175–184CrossRefPubMed

31.

Smith BD, Arthur DW, Buchholz TA et al (2009) Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 74:987–1001PubMed

32.

Antonucci JV, Wallace M, Goldstein NS et al (2009) Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow-up. Int J Radiat Oncol Biol Phys 74:447–452PubMed

33.

Polgar C, Major T, Fodor J et al (2010) Accelerated partial-breat irradiation using high-dose-rate interstitial brachytherapy: 12-year update of a prospective clinical study. Radiother Oncol 94:274–279CrossRefPubMed

34.

Finsterer H (1915) Zur therapie inoperable magen—und Darmkarzinome mit freilegund und nachfolgender Rontgenbestrahlung. Strahlentherapie 6:205–213

35.

Abe M, Takahashi M (1981) Intraoperative radiotherapy: the Japanese experience. Int J Radiat Oncol Biol Phys 7:863–868PubMed

36.

Vaidya JS, Baum M, Tobias JS et al (2001) Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer. Ann Oncol 12:1075–1080CrossRefPubMed

37.

Holmes DR, Baum M, Joseph D (2007) The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). Am J Surg 194:507–510CrossRefPubMed

38.

Sindelar WF, Johnstone PA, Hoekstra H (1999) Normal tissue tolerance to IORT: The NCI experimental studies. In: Gunderson LL, Willett CG, Harrison LB et al (eds) Intraoperative irradiation: techniques and results. Humana Press, Totowa, pp 131–146

39.

Rietjens M, De Lorenzi F, Veronesi P et al (2006) Breast conservative treatment in association with implant augmentation and intraoperative radiotherapy. J Plast Reconstr Aesthet Surg 59(5):532–555CrossRefPubMed

40.

Athas WF, Adams-Cameron M, Hunt WC et al (2000) Travel distance to radiation therapy and receipt of radiotherapy following breast conserving therapy. J Natl Cancer Inst 92:269–271CrossRefPubMed

41.

Fietkau R (2000) Effects of the time interval between surgery and radiotherapy on the treatment results. Strahlenther Onkol 176:452–457CrossRefPubMed

42.

Recht A, Come SE, Henderson IC et al (1996) The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 334:1356–1361CrossRefPubMed

43.

Hershman DL, Wang X, McBride R et al (2006) Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys 65:1353–1360PubMed

44.

Mikeljevic JS, Haward R, Johnston C et al (2004) Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery. Br J Cancer 90:1343–1348CrossRefPubMed

45.

Bellon JR, Come SE, Gelman RS et al (2005) Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 23:1934–1940CrossRefPubMed

46.

Mariani L, Salvadori B, Marubini E et al (1998) Ten year results of a randomised trial comparing two conservative treatment strategies for small size breast cancer. Eur J Cancer 34:1156–1162CrossRefPubMed

47.

Chism DB, Freedman GM, Li T et al (2006) Re-excision of margins before breast radiation-diagnostic or therapeutic? Int J Radiat Oncol Biol Phys 65:1416–1421PubMed

Titel: Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons
verfasst von: Umberto Veronesi
Roberto Orecchia
Alberto Luini
Viviana Galimberti
Stefano Zurrida
Mattia Intra
Paolo Veronesi
Paolo Arnone
Maria Cristina Leonardi
Mario Ciocca
Roberta Lazzari
Pietro Caldarella
Nicole Rotmensz
Claudia Sangalli
Daniele Sances
Patrick Maisonneuve
Publikationsdatum: 01.11.2010
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1115-5

Neu im Fachgebiet Onkologie

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Does race modify the association between CYP1B1 Val432Leu polymorphism and breast cancer risk? A critical appraisal of a recent meta-analysis

Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics

UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs

TMS, a chemically modified herbal derivative of Resveratrol, induces cell death by targeting Bax